Haleos LabsNSE:HALEOSLABS +2.06%68 Operating Margin % is 0.41% as of Mar. 2026, which is 94% below its 10-year median of 7.37. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 68/100 and a GF Value™ of ₹1,127.47 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 943 Biotechnology companies, Haleos Labs ranks better than 79.75% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Haleos Labs's Operating Income for the
three
months ended in Mar. 2026 was ₹3 Mil. Haleos Labs's Revenue for the
three
months ended in Mar. 2026 was ₹751 Mil. Therefore, Haleos Labs's Operating Margin % for the quarter that ended in Mar. 2026 was 0.41%.
Good Sign:
Haleos Labs Ltd operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Haleos Labs's Operating Margin % or its related term are showing as below:
NSE:HALEOSLABS'
s Operating Margin % Range Over the Past 10 Years
Min: 3.63 Med: 7.37 Max: 10.82
Current: 8.4
NSE:HALEOSLABS's Operating Margin % is ranked better than 79.75% of 943
companies
in the Biotechnology industry
Industry Median: -86.89
vs NSE:HALEOSLABS: 8.40
Haleos Labs's 5-Year Average Operating Margin % Growth Rate was 1.70% per year.
Haleos Labs's Operating Income for the
three
months ended in Mar. 2026 was ₹3 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was ₹280 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Haleos Labs Operating Margin % Related Terms
Haleos Labs Operating Margin % Historical Data
* Premium members only.
The historical data trend for Haleos Labs's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:HALEOSLABS vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Haleos Labs's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Haleos Labs's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Haleos Labs's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleos Labs (NSE:HALEOSLABS) has a Operating Margin % of 0.41% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Haleos Labs and its competitors. This is 94% below median its historical median of 7.37. Over the past decade, Haleos Labs' Operating Margin % has ranged from 3.63 to 10.82. According to the industry distribution chart, Haleos Labs ranks #191 out of 943 companies in the Biotechnology industry, placing it in the top 20.3%.
Is Haleos Labs' Operating Margin % too high?
Haleos Labs' current Operating Margin % of 0.41% is 94% below median its 10-year median of 7.37. Over the past 10 years, this metric has ranged from a low of 3.63 to a high of 10.82. Based on the distribution chart, Haleos Labs ranks #191 out of 943 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Haleos Labs has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #191 out of 943 companies for Operating Margin %. This places Haleos Labs in the top 20% of its industry — outperforming the majority of peers. Historically, Haleos Labs' own Operating Margin % has ranged from 3.63 to 10.82 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Haleos Labs and its competitors. Haleos Labs's current Operating Margin % is 0.41%, which is 94% below median its own 10-year median of 7.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,127.47, compared to a current price of ₹1,399.40 — trading 24.1% above its estimated fair value. The current Operating Margin % is 0.41%, which is 94% below median its 10-year median of 7.37. Haleos Labs' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current Operating Margin % is 0.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,399.40 is trading 24.1% above its estimated GF Value™ of ₹1,127.47.
GuruFocus considers Haleos Labs to be Modestly Overvalued.
Key valuation signals for NSE:HALEOSLABS:
Operating Margin %: 0.41% (94% below median its 10-year median of 7.37)
GF Value™: ₹1,127.47 vs. price of ₹1,399.40 (24.1% above fair value)
No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
68GF Score
Get the complete analysis for NSE:HALEOSLABS
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HALEOSLABS has been successfully added to your 
